



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hilda E. Smith

Serial No.: 10/632,117

Filed: July 31, 2003

For: ENVIRONMENTALLY REGULATED GENES OF STREPTOCOCCUS SUIS

Confirmation No.: 5350

Examiner: J. Hines

Group Art Unit: 1645

Attorney Docket No.: 2183-6055US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 14, 2007

Betty Vowles

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Other Documents

MIKAYAMA et al., Nov. 1993, Proc. Natl. Acad. Sci., USA., pp. 10056-60, Vol. 90. RUDINGER et al., Characteristics of the amino acids as components of a peptide hormone sequence, Peptide hormones, Biol. Council, June 1976, pp. 1-7.

Serial No.: 10/632,117

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.:

2183-5993.1US

Serial No.:

11/499,884

Filed:

8/3/2006

Title:

VIRULENCE OF STREPTOCOCCI

Attorney Docket No.:

2183-4726.1US

Serial No.:

11/516,691 9/5/2006

Filed: Title:

STREPTOCOCCUS SUIS VACCINES AND DIAGNOSTIC TESTS

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

I hereby certify that no item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the statement, and therefore no fee is due.

If, however, the Patent Office determines an amount is due, please debit TraskBritt Deposit Account No. 20-1469 for the fee.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: August 13, 2007

ACT/bv

Enclosures: Form PTO/SB/08

Cited Non-U.S. Patent Documents



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/632,117 INFORMATION DISCLOSURE Filing Date July 31, 2003 STATEMENT BY APPLICANT First Named Inventor Hilda E. Smith 1645 Group Art Unit (use as many sheets as necessary) Examiner Name J. Hines 2183-6055US Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		MIKAYAMA et al., Nov. 1993, Proc. Natl. Acad. Sci., USA., pp. 10056-60, Vol. 90.□			
		RUDINGER et al., Characteristics of the amino acids as components of a peptide hormone sequence, Peptide hormones, Biol. Council, June 1976, pp. 1-7.			
		·			
,					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.